[1] Slichter studied the performance of laboratory tests of platelet function such as the bleeding time.
[3] In patients with immune thrombocytopenia, Slichter infused radiolabeled autologous platelets and measured platelet-associated immunoglobulin levels.
She was also lead author on the Optimal Platelet Dose Strategy for Management of Thrombocytopenia (PLADO) trial,[9][10] which evaluated bleeding outcomes to determine the optimal frequency and dose of platelet transfusion for patients undergoing chemotherapy.
She continued to study how platelet dose, source (apheresis vs pooled), donor-recipient ABO compatibility, and duration of storage impacted bleeding outcomes in adults[11][12] and children.
[13] Slichter titled her autobiography Path of Persistence: Gender Trailblazer and Platelet Pioneer.